Kargluminsyra Waymade (Carglumic Acid)

Carglumic acid acts as an analog of N‑acetylglutamate, the essential activator of carbamoyl phosphate synthetase I. By binding to this enzyme, it restores its activity, enabling the first step of the mitochondrial urea cycle to convert ammonia into carbamoyl phosphate, thereby facilitating ammonia detoxification.

The dosage of Kargluminsyra Waymade is individualized and determined by the prescribing clinician based on the patient’s age, weight, severity of hyperammonemia, and renal function. Healthcare professionals set the appropriate regimen to achieve optimal ammonia control.

Safety data for carglumic acid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider close monitoring.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Unlike sodium phenylbutyrate or sodium benzoate, which remove nitrogen by forming alternative waste products, carglumic acid directly activates the urea cycle enzyme carbamoyl phosphate synthetase I. This mechanism can be more effective in patients with N‑acetylglutamate synthase deficiency, while other scavengers are often used when the urea cycle is partially functional.

Store Kargluminsyra Waymade at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

The medication is taken orally, usually with water. The exact timing relative to meals or other drugs should follow the prescribing clinician’s instructions to optimize absorption and therapeutic effect.

Serious adverse events, although rare, can include severe allergic reactions such as anaphylaxis, hepatic dysfunction, metabolic acidosis, and seizures. Patients should be monitored for any signs of these conditions, and treatment should be discontinued immediately if they occur.

Individuals with a known hypersensitivity to carglumic acid or any of its excipients should avoid the product. It is also contraindicated in patients where activation of carbamoyl phosphate synthetase I would be ineffective, such as those with complete enzyme deficiency unrelated to N‑acetylglutamate synthase.